Sat, Dec 20, 2014, 1:07 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Questcor Pharmaceuticals, Inc. (QCOR) Message Board

druid_of_scranton 3 posts  |  Last Activity: Nov 23, 2014 3:00 PM Member since: May 25, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • druid_of_scranton druid_of_scranton Nov 23, 2014 3:00 PM Flag

    QCOR shareholders got dilluted, but I'm not complaining. The Acthar franchise is not patented. Drugs with patents are ticking time bombs. It looks to me like most of MNK's other drugs are either so complex their formulations can't be easily duplicated or are already off patent.

    There is still a lot for QCOR shareholders to be happy with. And you can figure the bear raids are over now, because MNK is not compelling enough for those hedge funds to raid the share price so they can load up on the investment now.

    It looks like this is still a pretty fair investment.

  • druid_of_scranton druid_of_scranton Nov 23, 2014 2:59 PM Flag

    Longs are beating a dead horse on this generic reclassification IMO

    Methylphenidate ER is $54.7mm out of the $414.3mm in Specialty Pharmacy sales portion as of Q-2. Since then the QCOR acquisition adds $170mm to the specialty pharmacy quarterly sales total.

    Methylphenidate is a generic and the reclassification is due to variance in the show release portion of the formulation. Sales aren't going to end because of this reclassification and there is nothing to stop MNK from reformulating their generic with a slow release agent that meets the FDA guidelines.

    This is not really all that big a deal.

    Nobody is talking about the write down on the "Contract Media" portion of the business due to the cancellation of a large contract (which takes effect like 12 months from now.) That is a hit to earnings and to growth but taken as a whole, is not all that deadly. Maybe it looks like death by a thousand paper cuts, but isn't this just the pharmacy business as usual?

    This whole QCOR acquisition served to dilute the Acthar franchise that QCOR shareholders owned before the merger by about 150% due to the increase share count of the surviving company and the fact that Acthar profits generated less than 1/2 of total earnings now. (and the surviving company is a debt bomb). But we got thirty bucks cash.

    MNK, with all its setbacks is still 12 X next years earnings more or less.

    Continued

  • Reply to

    OT: NKA. NG Up Crude Fallin'

    by nomadinx Nov 19, 2014 9:43 PM
    druid_of_scranton druid_of_scranton Nov 20, 2014 12:22 AM Flag

    Normad NKA says that they lost their biggest customer, and that the distribution is likely to be halted next quarter. They also say that their storage leaks like a sieve.
    Why not stick with NTI, or CVRR or ALDW. Downstream from midstream. I remember you had NTI on one of your lists a year or so ago. I like it.

    Stay away form NKA imo

QCOR
93.600.00(0.00%)Aug 14 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
3M Company
NYSEFri, Dec 19, 2014 4:04 PM EST
ImmunoGen, Inc.
NASDAQFri, Dec 19, 2014 4:00 PM EST